Retinagenix Holdings

Retinagenix is a biotechnology company focused on developing innovative therapies for degenerative retinal diseases, including Stargardt disease and dry age-related macular degeneration. The company's primary approach involves the development of small molecule retinoid-based compounds designed to modulate the visual cycle and prevent the accumulation of toxic lipofuscin in the retinal pigment epithelium. By targeting specific receptors within the retinoid signaling pathway, Retinagenix aims to preserve vision and slow disease progression in patients with inherited and age-related retinal degenerations. The company is currently advancing its lead candidates through pre-clinical development to support future clinical trials.